DK2214666T3 - Fremgangsmåde til reducering af amyloid-afsætning, amyloid-neurotoksicitet og mikrogliose med (-)-nilvadipin-enantiomer - Google Patents

Fremgangsmåde til reducering af amyloid-afsætning, amyloid-neurotoksicitet og mikrogliose med (-)-nilvadipin-enantiomer

Info

Publication number
DK2214666T3
DK2214666T3 DK08836256.1T DK08836256T DK2214666T3 DK 2214666 T3 DK2214666 T3 DK 2214666T3 DK 08836256 T DK08836256 T DK 08836256T DK 2214666 T3 DK2214666 T3 DK 2214666T3
Authority
DK
Denmark
Prior art keywords
amyloid
enantiomes
nilvadipin
microgliosis
neurotoxicity
Prior art date
Application number
DK08836256.1T
Other languages
Danish (da)
English (en)
Inventor
Michael J Mullan
Daniel Paris
Robert A Ivey Iii
Original Assignee
Alzheimer S Inst Of America Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alzheimer S Inst Of America Inc filed Critical Alzheimer S Inst Of America Inc
Application granted granted Critical
Publication of DK2214666T3 publication Critical patent/DK2214666T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4422—1,4-Dihydropyridines, e.g. nifedipine, nicardipine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
DK08836256.1T 2007-10-05 2008-10-03 Fremgangsmåde til reducering af amyloid-afsætning, amyloid-neurotoksicitet og mikrogliose med (-)-nilvadipin-enantiomer DK2214666T3 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US97795307P 2007-10-05 2007-10-05
US4610908P 2008-04-18 2008-04-18
PCT/US2008/078786 WO2009046323A1 (en) 2007-10-05 2008-10-03 Method for reducing amyloid deposition, amyloid neurotoxicity, and microgliosis with (-)-nilvadipine enantiomer

Publications (1)

Publication Number Publication Date
DK2214666T3 true DK2214666T3 (da) 2014-01-27

Family

ID=40523447

Family Applications (1)

Application Number Title Priority Date Filing Date
DK08836256.1T DK2214666T3 (da) 2007-10-05 2008-10-03 Fremgangsmåde til reducering af amyloid-afsætning, amyloid-neurotoksicitet og mikrogliose med (-)-nilvadipin-enantiomer

Country Status (16)

Country Link
US (2) US8236346B2 (https=)
EP (1) EP2214666B1 (https=)
JP (1) JP5411145B2 (https=)
KR (1) KR101417200B1 (https=)
CN (1) CN101883564B (https=)
AU (1) AU2008308519B2 (https=)
BR (1) BRPI0817516A2 (https=)
CA (1) CA2701620C (https=)
DK (1) DK2214666T3 (https=)
ES (1) ES2449594T3 (https=)
MX (1) MX2010003669A (https=)
NZ (1) NZ584729A (https=)
PL (1) PL2214666T3 (https=)
RU (1) RU2490014C2 (https=)
TW (1) TWI500422B (https=)
WO (1) WO2009046323A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20140286910A1 (en) * 2013-03-19 2014-09-25 Nikolai Tankovich Stem cells and methods incorporating environmental factors as a means for enhancing stem cell proliferation and plasticity
CN112826794B (zh) 2019-11-06 2022-02-11 上海交通大学医学院 一种靶向修复神经血管病变的纳米复合物及其制备与应用

Family Cites Families (61)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4338322A (en) * 1975-07-02 1982-07-06 Fujisawa Pharmaceutical Co., Ltd. 1,4-Dihydropyridine derivatives, pharmaceutical compositions containing same and methods of effecting vasodilation using same
JPS6038322A (ja) * 1983-08-11 1985-02-27 Fujisawa Pharmaceut Co Ltd ジヒドロピリジンａ物質含有易溶性固形製剤
JPS61129140A (ja) 1984-11-27 1986-06-17 Nitto Electric Ind Co Ltd 医薬組成物
GB8431119D0 (en) * 1984-12-10 1985-01-16 Fujisawa Pharmaceutical Co Anti-arteriosclerotic composition
US4940556A (en) 1986-01-30 1990-07-10 Syntex (U.S.A.) Inc. Method of preparing long acting formulation
US4992445A (en) * 1987-06-12 1991-02-12 American Cyanamid Co. Transdermal delivery of pharmaceuticals
US5114946A (en) * 1987-06-12 1992-05-19 American Cyanamid Company Transdermal delivery of pharmaceuticals
US5001139A (en) * 1987-06-12 1991-03-19 American Cyanamid Company Enchancers for the transdermal flux of nivadipine
EP0294601B1 (en) 1987-06-12 1993-01-20 American Cyanamid Company Transdermal delivery of pharmaceuticals
US5045553A (en) * 1987-06-24 1991-09-03 Fujisawa Pharmaceutical Company, Ltd. Pharmaceutical composition for percutaneous drug absorption and percutaneous drug absorption promoter
US4820720A (en) * 1987-08-24 1989-04-11 Alza Corporation Transdermal drug composition with dual permeation enhancers
US5508413A (en) * 1987-08-27 1996-04-16 Fujisawa Pharmaceutical Co., Ltd. (+)-5-isopropyl 3-methyl 2-cyano-6 methyl-4-(3-nitrophenyl)-1, 4-dihydropyridine-3, 5-dicarboxylate
ATE76292T1 (de) 1987-11-25 1992-06-15 American Cyanamid Co System fuer die verzoegerte (kontrollierte) freisetzung von substituierten dihydropyridincalciumantagonisten.
US5160734A (en) * 1987-11-25 1992-11-03 American Cyanamid Company Sustained release delivery system for substituted dihydropyridine calcium channel blockers
US4902514A (en) * 1988-07-21 1990-02-20 Alza Corporation Dosage form for administering nilvadipine for treating cardiovascular symptoms
JP2718105B2 (ja) 1988-10-27 1998-02-25 藤沢薬品工業株式会社 （＋）−２−シアノ−６−メチル−４−（３−ニトロフェニル）−１，４−ジヒドロピリジン−３，５−ジカルボン酸５−イソプロピル３−メチルの光安定性結晶
WO1990011761A1 (en) * 1989-03-31 1990-10-18 The Children's Medical Center Corporation Treatment of aids dementia, myelopathy and blindness
JPH0381262A (ja) 1989-08-23 1991-04-05 Yamanouchi Pharmaceut Co Ltd ジヒドロピリジン系カルシウム拮抗薬の光学活性体の製造法
JP2867462B2 (ja) 1989-09-12 1999-03-08 藤沢薬品工業株式会社 経皮吸収用製剤
JP2920956B2 (ja) 1989-10-06 1999-07-19 藤沢薬品工業株式会社 ニルバジピン含有持続性錠剤
US5258393A (en) * 1990-02-21 1993-11-02 Fujisawa Pharmaceutical Co., Ltd. Use of a dihydropyridine compound for improving inner ear microcirculation
JPH06500554A (ja) 1990-08-23 1994-01-20 ザ・チルドレンズ・メディカル・センター・コーポレイション エイズ性痴呆、脊髄障害、末梢神経障害、および視覚喪失の治療
WO1993005770A1 (fr) 1991-09-20 1993-04-01 Fujisawa Pharmaceutical Co., Ltd. Preparation a longue duree d'action
JPH05139974A (ja) 1991-11-26 1993-06-08 Fujisawa Pharmaceut Co Ltd ジヒドロピリジンａ物質含有易溶性固体分散体の製造法
US5834496A (en) * 1991-12-02 1998-11-10 Sepracor, Inc. Methods for treating hypertension using optically pure S(-) felodipine
DE4141646A1 (de) 1991-12-17 1993-06-24 Klinge Co Chem Pharm Fab Arzneimittelkombination mit synergistischer wirkung, verfahren zu seiner herstellung und seine verwendung
US5340591A (en) * 1992-01-24 1994-08-23 Fujisawa Pharmaceutical Co., Ltd. Method of producing a solid dispersion of the sparingly water-soluble drug, nilvadipine
DE4229805A1 (de) 1992-09-07 1994-03-24 Werner E G Prof Dr Mueller Kalzium-Kanal-Antagonisten oder deren Derivate zur Herstellung eines Arzneimittels zur Bekämpfung von Erkrankungen, die durch Prion-Proteine oder Prion-analoge Proteine ausgelöst werden
US5721263A (en) * 1993-06-07 1998-02-24 Takeda Chemical Industries, Ltd. Pharmaceutical composition for angiotensin II-mediated diseases
CA2125251C (en) 1993-06-07 2005-04-26 Yoshiyuki Inada A pharmaceutical composition for angiotensin ii-mediated diseases
AU682192B2 (en) * 1993-06-30 1997-09-25 Fujisawa Pharmaceutical Co., Ltd. Encapsulated medicine
US6334997B1 (en) * 1994-03-25 2002-01-01 Isotechnika, Inc. Method of using deuterated calcium channel blockers
EP0911027A4 (en) * 1996-04-26 2000-11-29 Fujisawa Pharmaceutical Co THE DIHYDROPYRIDINE CONTAINS TO IMPROVE THE CIRCULATION OF THE EYE-SURROUNDING TISSUE
US6271259B1 (en) * 1996-05-07 2001-08-07 Ito En, Ltd. Method for improving the brain function, inhibiting glutamate excitotoxicity and rescuing from neuronal death
KR100222306B1 (ko) 1996-11-20 1999-10-01 이병언 닐바디핀 속효성 고형제제 및 이의 제조방법
US6541479B1 (en) * 1997-12-02 2003-04-01 Massachusetts College Of Pharmacy Calcium channel blockers
JP2002517440A (ja) 1998-06-08 2002-06-18 アドバンスド メディスン インコーポレーテッド 新規カルシウムチャンネル薬物および用途
CA2319142A1 (en) * 1998-06-08 1999-12-16 Advanced Medicine, Inc. Novel therapeutic agents for membrane transporters
NZ509260A (en) 1998-07-10 2003-09-26 Novartis Ag Pharmaceutical composition containing valsartan and a calcium channel blocker
WO2001064250A1 (en) 2000-03-03 2001-09-07 Fujisawa Pharmaceutical Co., Ltd. Remedies for malignant tumor-concomitant neurosis and azoor or analogous diseases thereof
ES2287110T3 (es) 2000-04-11 2007-12-16 Sankyo Company, Limited Composicion farmaceutica estabilizada que contiene un bloqueador de calcio consistente en azelnidipina.
JP2001335483A (ja) 2000-05-30 2001-12-04 Nichiko Pharmaceutical Co Ltd ニルバジピン含有製剤
AU2001278045B2 (en) * 2000-07-27 2006-08-03 Pharmacia Corporation Epoxy-steroidal aldosterone antagonist and calcium channel blocker combination therapy for treatment of congestive heart failure
JP3968687B2 (ja) 2000-09-13 2007-08-29 東和薬品株式会社 易吸収性ニルバジピン錠
JP3470096B2 (ja) 2000-09-19 2003-11-25 沢井製薬株式会社 ニルバジピン含有易溶性固形製剤およびその製造法
EP1343506A1 (de) * 2000-12-19 2003-09-17 MERCK PATENT GmbH Pharmazeutische formulierung enthaltend pyrazolo 4,3-d]pyrimidine und antithrombotica, calcium-antagonisten, prostaglandine oder prostaglandinderivate
US20040072846A1 (en) * 2000-12-19 2004-04-15 Hans-Michael Eggenweiler Pharmaceutical formulation containing thienopyrimidines and antithrombotics, calcium antagonists, prostaglandins or prostaglandin derivatives
US7083642B2 (en) * 2000-12-22 2006-08-01 Avantec Vascular Corporation Delivery of therapeutic capable agents
CA2333494A1 (en) 2001-02-01 2002-08-01 Vasogen Ireland Limited Blood brain barrier modulation
ES2275007T3 (es) 2001-05-25 2007-06-01 Schering Corporation Uso de derivados de azetidinona sustitudos en el tratamiento de la enfermedad de alzeimer.
EP1426051B1 (en) * 2001-09-11 2008-07-16 Asahi Kasei Pharma Corporation Medicinal composition for prevention of or treatment for cerebrovascular disorder
EG24716A (en) 2002-05-17 2010-06-07 Novartis Ag Combination of organic compounds
WO2004034963A2 (en) 2002-05-17 2004-04-29 Eisai Co., Ltd. Methods and compositions using cholinesterase inhibitors
DK1507558T3 (da) 2002-05-17 2011-12-05 Novartis Pharma Ag Farmaceutisk sammensætning omfattende en renininhibitor, en calciumkanalblokker og et diuretikum
PE20040468A1 (es) 2002-05-17 2004-09-14 Novartis Ag Combinacion de compuestos organicos
JP2003146878A (ja) 2002-11-22 2003-05-21 Sawai Pharmaceutical Co Ltd ニルバジピン含有易溶性固形製剤およびその製造法
US20050031651A1 (en) * 2002-12-24 2005-02-10 Francine Gervais Therapeutic formulations for the treatment of beta-amyloid related diseases
EP1585520A1 (en) 2002-12-24 2005-10-19 Neurochem (International) Limited Therapeutic formulations for the treatment of beta-amyloid related diseases
CA2525970C (en) * 2003-05-15 2011-03-22 Roskamp Research, Llc Use of nilvadipine for reducing amyloid deposition, amyloid neurotoxicity and microgliosis
JP2004002460A (ja) 2003-07-29 2004-01-08 Towa Yakuhin Kk 易吸収性ニルバジピン錠の製造法
WO2009046338A1 (en) * 2007-10-05 2009-04-09 Roskamp Research Llc Method for increasing cerebral blood flow with (+)-nilvadipine enantiomer

Also Published As

Publication number Publication date
KR20100067683A (ko) 2010-06-21
CN101883564A (zh) 2010-11-10
TWI500422B (zh) 2015-09-21
AU2008308519A2 (en) 2010-04-29
CA2701620A1 (en) 2009-04-09
CA2701620C (en) 2014-12-09
US20090092667A1 (en) 2009-04-09
KR101417200B1 (ko) 2014-08-01
EP2214666B1 (en) 2013-12-11
NZ584729A (en) 2012-12-21
ES2449594T3 (es) 2014-03-20
JP2010540661A (ja) 2010-12-24
WO2009046323A1 (en) 2009-04-09
RU2010117634A (ru) 2011-11-10
CN101883564B (zh) 2013-10-16
US8236347B2 (en) 2012-08-07
US8236346B2 (en) 2012-08-07
EP2214666A4 (en) 2010-12-08
BRPI0817516A2 (pt) 2015-06-16
AU2008308519A1 (en) 2009-04-09
PL2214666T3 (pl) 2014-06-30
RU2490014C2 (ru) 2013-08-20
JP5411145B2 (ja) 2014-02-12
EP2214666A1 (en) 2010-08-11
AU2008308519B2 (en) 2014-09-11
US20100183711A1 (en) 2010-07-22
MX2010003669A (es) 2010-11-25
TW200920364A (en) 2009-05-16

Similar Documents

Publication Publication Date Title
DK2510843T3 (da) System, kapsel og fremgangsmåde til fremstilling af en drikkevare
BRPI0912799A2 (pt) fluxímetro, e, método
DK3181134T3 (da) Bifidobakterier til behandling af diabetes og relaterede tilstande
BRPI0814466A2 (pt) Método.
BRPI0814467A2 (pt) Método, e, biocombustível
DK2475356T3 (da) Anordninger, systemer og fremgangsmåder til justering af fluidtilførselsparametre
BRPI0814359A2 (pt) Método
BRPI0817226A2 (pt) Método
BRPI0817726A2 (pt) Método
DK2446090T3 (da) Indretning og fremgangsmåde til reducering af støj
DK2270818T3 (da) Polyelektrolyt og fremgangsmåde til fremstilling af polyelektrolytten
DK2451839T3 (da) Fremgangsmåde til produktion af variable domæner
DK2044002T3 (da) Fremgangsmåde til fremstilling af 3-substituerede 2-amino-5-halobenzamider
DK3081315T3 (da) Fremgangsmåde og system til sortering af fødevarer
BRPI0913227A2 (pt) método, e objeto
DK2068927T3 (da) Fremgangsmåder til reducering af eosinofilniveauer
BRPI0809573A2 (pt) composição, e, método
BRPI0913112A2 (pt) fluxímetro, e, método.
DK2095717T3 (da) Fremgangsmåde til fremstilling af fermenteret mælk, og fermenteret mælk
DK2391589T3 (da) Sulfoaluminatklinker og fremgangsmåde til fremstilling af samme
DK2865422T3 (da) Alpha-msh-derivater til behandling af fotodermatoser
DK2147160T3 (da) Fremgangsmåde og maskine til nedsænkning af en skinne
BRPI0814167A2 (pt) Composição, e, método
DK2358661T3 (da) Fremgangsmåde til fremstilling af trans-4-amino-cyclohexyl-eddikesyreethylester-hcl
DK2342346T3 (da) Thermotoga til behandling af biomasse